๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone propionate and salmeterol

โœ Scribed by Peter T. Daley-Yates; David A. Parkins

Book ID
108642740
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
376 KB
Volume
72
Category
Article
ISSN
0306-5251

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combination particles containing salmete
Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment
โœ Regina Westmeier; Hartwig Steckel ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 397 KB

A precipitation process is used to produce combined particles consisting of two antiasthmatic drugs: salmeterol xinafoate and fluticasone propionate. To control the crystallisation of these particles, a micromixer is used to mix solvent and antisolvent flow. To produce particles in the respirable ra

Dry powder formulations for inhalation o
Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals
โœ Darragh Murnane; Gary P. Martin; Christopher Marriott ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 307 KB

Direct crystallization of active pharmaceutical ingredient (API) particles in the inhalable size range of 1-6 microm may overcome surface energization resulting from micronization. The aerosolization of fluticasone propionate (FP) and salmeterol xinafoate (SX) microcrystals produced by aqueous cryst